Resveratrol has become a major focus of biomedical research over the past two decades. This interest was initially based on reproducible epidemiological investigations showing an inverse relationship between the consumption of red wine and various types of cardiovascular disease (Mochly-Rosen and Zakhari, 2010; Ramprasath and Jones, 2010; Tosun and Ikaya, 2010). According to the Web of Science Database the first citation of resveratrol was in 1977. Scientific interest in resveratrol grew slowly

more »

... with approximately 200 cumulative citations over the next 15 years. However, from the mid 1990s to the present this field has expanded considerably. For example, in the year 2001 alone there were nearly 3100 citations concerning resveratrol. In 2009 this number had jumped to nearly 18,000 (Figure 1) with 2010 projected to easily exceed 20,000 citations. These citations are based on the publication of now over 5000 articles on resveratrol in the biomedical literature (Figure 2). REFERENCES Alfaras, I., Juan, M.E., and Planas, J.M. (2010). Transresveratrol reduces precancerous colonic lesions in dimethylhydrazine-treated rats. J. Agri. Food Chem., 58:8104-8110. Calabrese, E.J. (2010). Hormesis is central to toxicology, pharmacology and risk assessment. Hum. Exper. Toxicol., 29:249-261. Calabrese, E.J. (2009a). Getting the dose response wrong. Why hormesis became marginalized and the threshold model accepted. Arch. Toxicol., 83:227-247. Calabrese, E.J. (2009b). The road to linearity: Why linearity at low doses became the basis for carcinogen risk assessment. Arch. Toxicol., 83:203-225. Calabrese, E.J., and Baldwin, L.A. (2003a). Toxicology rethinks its central belief -Hormesis demands a reappraisal of the way risks are assessed. Nature, 421:691-692. Calabrese, E.J., and Baldwin, L.A. (2003b). The hormetic dose response model is more common than the threshold model in toxicology. Tox. Sci., 71:246-250. Calabrese, E.J., and Baldwin, L.A. (2003bc). Hormesis: the dose-response revolution. Ann. Rev. Pharmacol.